TABLE 2.
Reasons for vedolizumab discontinuation
| Reason for discontinuation | Elderly | Nonelderly | p value |
|---|---|---|---|
| Ineffectiveness on intestinal disease, n (%) | 71 (71.7) | 118 (75.2) | ns |
| Adverse events, n (%) | 18 (18.2) | 14 (8.8) | 0.026 |
| Ineffectiveness on EIMs, n (%) | 3 (3.0) | 8 (5.0) | ns |
| Ineffectiveness on perianal disease, n (%) | 2 (2.0) | 5 (3.2) | ns |
| Remission, n (%) | 1 (1.0) | 0 (0.0) | ns |
| Other, n (%) | 4 (4.0) | 14 (8.8) | ns |
| CD | |||
| Ineffectiveness on intestinal disease, n (%) | 30 (62.5) | 56 (67.5) | ns |
| Adverse events, n (%) | 10 (20.8) | 7 (8.4) | 0.026 |
| Ineffectiveness on EIMs, n (%) | 3 (6.3) | 6 (7.2) | ns |
| Ineffectiveness on perianal disease, n (%) | 2 (4.2) | 5 (6.0) | ns |
| Remission, n (%) | 1 (2.1) | 0 (0.0) | ns |
| Other, n (%) | 2 (4.2) | 9 (10.8) | ns |
| UC | |||
| Ineffectiveness on intestinal disease, n (%) | 41 (80.5) | 62 (81.6) | ns |
| Adverse events, n (%) | 8 (15.7) | 7 (9.2) | ns |
| Ineffectiveness on EIMs, n (%) | 0 (0.0) | 2 (2.6) | ns |
| Ineffectiveness on perianal disease, n (%) | 0 (0.0) | 0 (0.0) | ns |
| Remission, n (%) | 0 (0.0) | 0 (0.0) | ns |
| Other, n (%) | 2 (3.9) | 5 (6.6) | ns |
Note: For 10 patients, two reasons for discontinuation were specified: 4 elderly CD (2 ineffectiveness on intestinal disease + ineffectiveness on EIMs, 1 ineffectiveness on intestinal disease + adverse event, 1 ineffectiveness on intestinal disease + ineffectiveness on perianal disease), 5 nonelderly CD (1 ineffectiveness on intestinal disease + ineffectiveness on EIMs, 1 ineffectiveness on intestinal disease + adverse event, 1 ineffectiveness on intestinal disease + ineffectiveness on perianal disease, 1 ineffectiveness on EIMs + adverse event, 1 adverse event + other), 1 nonelderly UC (ineffectiveness on intestinal disease + ineffectiveness on EIMs).